RRM1、ERCC1蛋白表达与晚期NSCLC患者GP方案化疗疗效及预后相关性分析  

Relationship of expressions of RRM1 and ERCC1 proteins with response and prognosis in advanced NSCLC patients receiving cisplatin combined with gemcitabine chemotherapy

作　　者：杨宁[1] 韩俊庆[1] 盛巍[1] 

机构地区：[1]山东大学附属省立医院肿瘤中心,济南250021

出　　处：《山东大学学报（医学版）》2011年第6期89-93,共5页Journal of Shandong University:Health Sciences

摘　　要：目的探讨RRM1、ERCC1蛋白表达与晚期(IIIB～IV)非小细胞肺癌(NSCLC)吉西他滨联合顺铂(GP)方案化疗疗效及预后的关系。方法回顾性分析47例曾接受GP方案化疗的晚期NSCLC患者的临床病理资料,采用免疫组织化学法检测病理标本中RRM1、ERCC1蛋白表达,对化疗疗效及生存时间进行分析。结果 RRM1、ERCC1蛋白阳性率分别为46.81%(22/47)、42.55%(20/47),其表达与性别、年龄、PS评分、组织学类型、分期、吸烟均无相关性,化疗有效率为36.17%(17/47),RRM1、ERCC1蛋白阳性及阴性患者化疗有效率分别为18.18%(4/22)和52.00%(13/25),20.00%(4/20)和48.15%(13/27),差异有统计学意义(P=0.016、0.047)。RRM1、ERCC1蛋白低表达者中位生存期皆为14.1个月,RRM1、ERCC1蛋白高表达者中位生存期分别为6.8、7.1个月(P=0.008、0.017);RRM1、ERCC1蛋白均阴性表达者的预后明显好于1个或2个阳性表达者,中位生存期分别为14.8、7.6个月(P=0.012)。COX回归分析显示,分期是晚期NSCLC的独立预后影响因素。结论 RRM1、ERCC1表达水平与NSCLC患者GP方案的化疗近期疗效及预后为负相关关系,RRM1、ERCC1低表达的晚期NSCLC患者更能从GP方案中获益。Objective To explore the relationship of expressions of ribonucleotide reductase M1 RRM1 and excision repair cross complementation 1 （ERCC1） proteins with response and prognosis of patients with advanced（ⅢB-IV） nonsmall cell lung cancer （NSCLC） receiving cisplatin combined with gemcimbine （GP） chemotherapy. Methods Clinical pathological data from 47 advanced NSCLC patients who received GP chemotherapy were retrospectively analyzed, and their tumor samples were collected. Expressions of RRM1 and ERCC1 proteins in tumor samples were detected by method. The therapeutic effect and survival time were analyzed. Results RRM1 and ERCC1 positive rates were 46.81% （22/47） and 42.55% （20/47）, respectively. There was no correlation of RRM1 and ER- CC1 expressions with gender, age, PS scores, pathological type, TNM stage and smoking. The overall response rate was 36.17% （17/47）. Response rates were 18.18% （4/22） and 52.00% （ 13/25 ） respectively in patients with high and low RRM1 expressions （P = 0.016）, while they were 20.00% （4/20） and 48.15 % （13/27）in patients with high and low ERCC1 expressions, respectively （ P = 0.047）. Low expression of RRM1 or ERCC1 protein was correlated with longer median overall survival （ 14.1 months, 14.1 months）, while the median overall survival of high expression of RRM1 or ERCC1 protein was 6.8months and 7. lmonths, respectively（ P = 0. 008 , 0. 017 ）. Patients with low expressions of both RRM1 and ERCC1 proteins had longer median overall survival（ 14.8 months） than those with high expressions of RRM1 and/or ERCC1 （7.6months）（P =0.012）. Cox regression analysis revealed that the TNM stage was an independent prognostic factor, Conclusions Expressions of RRM1 and ERCC1 proteins have a negative correction with the response to GP chemotherapy and prognosis. Advanced NSCLC patients with low expression of RRM1 or ERCC1 may get more benefits from GP chemotherapy.

关 键 词：肺肿瘤 免疫组织化学 基因 吉西他滨/顺铂 

分 类 号：R734.2[医药卫生—肿瘤]